Mirum Pharmaceuticals Files 8-K: Material Agreement & Equity Sales
Ticker: MIRM · Form: 8-K · Filed: Dec 19, 2025 · CIK: 1759425
Sentiment: neutral
Topics: material-agreement, equity-sale, 8-k
TL;DR
Mirum Pharma inked a big deal & sold stock, filing an 8-K on Dec 18th.
AI Summary
Mirum Pharmaceuticals, Inc. announced on December 18, 2025, the entry into a material definitive agreement and unregistered sales of equity securities. The filing also includes Regulation FD Disclosure and Financial Statements and Exhibits. The company is incorporated in Delaware and its principal executive offices are located in Foster City, California.
Why It Matters
This 8-K filing indicates significant corporate actions by Mirum Pharmaceuticals, including a material definitive agreement and unregistered equity sales, which could impact its financial structure and future operations.
Risk Assessment
Risk Level: medium — The filing details a material definitive agreement and unregistered equity sales, which can introduce financial and operational risks.
Key Numbers
- 2834 — SIC Code (Pharmaceutical Preparations industry classification)
- 1231 — Fiscal Year End (Indicates the end of the company's financial reporting year)
Key Players & Entities
- Mirum Pharmaceuticals, Inc. (company) — Registrant
- December 18, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of Incorporation
- Foster City, California (location) — Address of Principal Executive Offices
- 001-38981 (company_id) — Commission File Number
FAQ
What is the nature of the material definitive agreement announced by Mirum Pharmaceuticals?
The filing does not specify the details of the material definitive agreement, only that one has been entered into.
What type of equity securities were sold in the unregistered sale?
The filing mentions unregistered sales of equity securities but does not specify the type of securities.
What is the significance of the Regulation FD Disclosure mentioned in the filing?
Regulation FD Disclosure ensures that material information is broadly disseminated to the public, preventing selective disclosure.
When was the 8-K form filed with the SEC?
The 8-K form was filed as of December 19, 2025.
What is Mirum Pharmaceuticals' primary business according to its SIC code?
Mirum Pharmaceuticals' SIC code is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 1,592 words · 6 min read · ~5 pages · Grade level 13.8 · Accepted 2025-12-19 08:30:15
Key Financial Figures
- $0.0001 — ich registered Common stock, par value $0.0001 per share MIRM Nasdaq Global Market
- $68,480,000 — e gross purchase price of approximately $68,480,000 (the "Private Placement"). The purchase
- $68.48 — ). The purchase price per PIPE Share is $68.48. As used herein, "Closing" means the cl
Filing Documents
- d53644d8k.htm (8-K) — 37KB
- d53644dex101.htm (EX-10.1) — 111KB
- d53644dex102.htm (EX-10.2) — 131KB
- d53644dex991.htm (EX-99.1) — 9KB
- g53644g1219081424656.jpg (GRAPHIC) — 3KB
- 0001193125-25-325825.txt ( ) — 477KB
- mirm-20251218.xsd (EX-101.SCH) — 3KB
- mirm-20251218_lab.xml (EX-101.LAB) — 18KB
- mirm-20251218_pre.xml (EX-101.PRE) — 11KB
- d53644d8k_htm.xml (XML) — 4KB
Forward-Looking Statements
Forward-Looking Statements This Form 8-K contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Generally, the words "anticipate," "estimate," "expect," "project," "intend," "plan," "contemplate," "predict," "forecast," "likely," "believe," "target," "will," "could," "would," "should," "potential," "may," "guidance," "designed" and similar expressions or their negative, may, but are not necessary to, identify forward-looking statements. Such forward-looking statements include, but are not limited to, those regarding the anticipated occurrence, manner and timing of the Mergers and the Private Placement. These forward-looking statements are based upon the Company's current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks and uncertainties inherent with the acquisition of companies, including the potential risks that regulatory approval will not be timely received (if at all) and the failure to satisfy or waive closing conditions; the risks and uncertainties inherent with private placements; the risks and uncertainties associated with the Company's business in general; and the impact of geopolitical and macroeconomic events on the Company's business. Other factors that might cause such a difference include those discussed in the Company's filings with the SEC, which include its Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. All forward-looking statements made herein are based on information currently available to the Company as of the date of this Report. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 10.1 Form of Subscription Agreement 10.2 Form of Registration Rights Agreement 99.1 Press Release, dated December 19, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Mirum Pharmaceuticals, Inc. Date: December 19, 2025 By: /s/ Eric Bjerkholt Eric Bjerkholt Chief Financial Officer